Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Cut to Hold at Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Other research analysts have also recently issued research reports about the company. Wedbush reissued an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. Citigroup started coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.80.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $28.04 on Friday. Kiniksa Pharmaceuticals International has a 1-year low of $17.38 and a 1-year high of $30.69. The company has a market capitalization of $2.05 billion, a P/E ratio of -112.16 and a beta of 0.06. The firm’s 50 day simple moving average is $26.79 and its 200 day simple moving average is $22.63.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The firm had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same quarter in the prior year, the firm earned ($0.25) EPS. The business’s revenue for the quarter was up 72.5% compared to the same quarter last year. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 8,212 shares of the firm’s stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $30.36, for a total transaction of $249,316.32. Following the completion of the transaction, the director now owns 12,546 shares of the company’s stock, valued at approximately $380,896.56. This trade represents a 39.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $20.48, for a total transaction of $245,760.00. Following the transaction, the chief operating officer now owns 77,363 shares of the company’s stock, valued at $1,584,394.24. The trade was a 13.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 440,863 shares of company stock worth $12,101,029 in the last three months. 53.48% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC raised its stake in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after buying an additional 568 shares during the last quarter. US Bancorp DE bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter valued at $33,000. Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter valued at $41,000. Wealthquest Corp purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth about $42,000. Finally, Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International in the 4th quarter worth about $61,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.